Nrx Pharmaceuticals, Inc. (NRXP) Stock Price & Analysis

Nrx Pharmaceuticals, Inc. (NRXP) fell 8.76% to USD 3.75 as of July 25, 2026 at 13:16 UTC, according to Nexqual real-time market data.

NRXP last closed at USD 4.11; the session ranged USD 3.75–4.18 on volume of 779,276 shares. Market capitalization is $160.50M, with a 52-week range of USD 1.62–5.06 (NCM). Source: Nexqual, July 25, 2026 at 13:16 UTC.

Key Statistics (as of July 25, 2026 at 13:16 UTC)

Technical Analysis (NRXP)

Nexqual's technical model rates NRXP "SELL" based on 2 bullish and 4 bearish signals across 125 daily candles, as of July 25, 2026 at 13:16 UTC.

Analyst Ratings (NRXP)

Wall Street analysts rate NRXP "None" based on 4 analysts, with a mean price target of USD 42 (range USD 25–49), per Nexqual as of July 25, 2026 at 13:16 UTC.

Earnings (NRXP)

Recent Earnings History

Source: Nexqual, July 25, 2026 at 13:16 UTC.

Financials & Fundamentals (NRXP)

Source: Nexqual, July 25, 2026 at 13:16 UTC.

Financial Health Score (NRXP)

Nexqual rates Nrx Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 13:16 UTC.

Ownership (NRXP)

Source: Nexqual, July 25, 2026 at 13:16 UTC.

Leadership (NRXP)

Nrx Pharmaceuticals, Inc. is led by Jonathan C. Javitt M.D., M.P.H. (age 68), Co-Founder, Chairman & CEO, per Nexqual as of July 25, 2026 at 13:16 UTC.

Major Backers & Investors (NRXP)

Notable institutional backers of Nrx Pharmaceuticals, Inc. include B Group, Inc. , AdvisorShares Trust-AdvisorShares Psychedelics ETF, AdvisorShares Investments, LLC, according to Nexqual as of July 25, 2026 at 13:16 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, July 25, 2026 at 13:16 UTC.

From Nrx Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-23)

Key Strengths & Strategy (as disclosed to the SEC)

• Founded in 2018, Dura offers precision-based interventional psychiatry services, including ketamine infusion therapy, TMS, Spravato®, stellate ganglion blocks, and psychotherapy.   On October 17, 2025, the Company completed the previously announced addition of Cohen and Associates, based in Sarasota, FL, to the HOPE Network with a strategic minority investment, which expanded HOPE's footprint on the West Coast of Florida, and related appointment of Dr.
• During 2025, the FDA gave a far broader Fast Track Designation to NRX-100, designating it for "Treatment of suicidal ideation in depression, including bipolar depression," According to the US Centers for Disease Control (CDC), 3.6 million Americans contemplate suicide each year, with 1.5 million attempting suicide and an American dying of suicide every 11 minutes.   NRx previously guided that it intended to seek only accelerated approval of NRX-100.
• For example, the FDA may require post-marketing testing, including Phase IV clinical trials and surveillance to further assess and monitor the product's safety and effectiveness after commercialization.   In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies and list drugs manufactured at their facilities with the FDA.
• With recent positive changes in the regulatory environment, we similarly anticipate entering the innovative market for ketamine in late 2026.   Our proprietary, preservative free formulation is the subject of a US patent filing that has potential to confer market exclusivity.

Partnerships

• In October of 2022 the Company submitted a Module 3 IND amendment to the FDA, allowing it to manufacture clinical supplies in the U.S.   In December 2022, as part of our agreement with Relief Therapeutics we transferred all manufacturing rights and know-how that we acquired for ZYESAMI (aviptadil) to Relief, including our collaborations with Nephron Pharmaceuticals and Alcami as contract manufacturers, and with the Polypeptide Group as a supplier of active pharmaceutical ingredient ("API").
• FDA further agreed to review Real World Evidence developed in partnership with Osmind, Inc. as confirmatory evidence of efficacy.   7 Table of Contents   NRx intends to seek accelerated approval of NRX-100.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 13:16 UTC. This page is informational and not investment advice.